methylphenidate has been researched along with Dementia in 20 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In designing the Apathy in Dementia Methylphenidate Trial (ADMET), a trial to evaluate the efficacy and safety of methylphenidate for the treatment of apathy in Alzheimer disease, we encountered the following issues: defining and measuring apathy, distinguishing apathy and depression, determining an appropriate test treatment, selecting relevant secondary outcomes, recruiting participants, and deciding on a suitable method for treatment unmasking." | 9.17 | Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET). ( Bachman, D; Drye, LT; Herrmann, N; Lanctôt, KL; Mintzer, JE; Rosenberg, PB; Scherer, RW, 2013) |
| "Methylphenidate was effective in 'normalizing' the decision-making behavior of patients, such that they became less risk taking on medication, although there were no significant effects on other aspects of cognitive function, including working memory, attentional set shifting, and reversal learning." | 6.72 | Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. ( Clark, L; Hodges, JR; Mehta, MA; Nestor, PJ; Rahman, S; Robbins, TW; Sahakian, BJ, 2006) |
| "Frontotemporal dementia is an underdiagnosed illness with predominant behavioral and executive manifestations." | 5.32 | Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study. ( Goforth, HW; Konopka, L; O'Donnell, K; Patel, R; Poprawski, T; Primeau, M; Rao, M; Ruth, A; Shirazi, P, 2004) |
| " Studies in early radiotherapy treatment phase (five studies) Pharmacological studies in the "early radiotherapy treatment phase" were designed to prevent or ameliorate cognitive deficits and included drugs used in dementia (memantine) and fatigue (d-threo-methylphenidate hydrochloride)." | 5.22 | Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. ( Brown, PD; Day, J; Gehring, K; Grosshans, D; Kirkman, MA; Li, J; Taphoorn, M; Zienius, K, 2022) |
| "In designing the Apathy in Dementia Methylphenidate Trial (ADMET), a trial to evaluate the efficacy and safety of methylphenidate for the treatment of apathy in Alzheimer disease, we encountered the following issues: defining and measuring apathy, distinguishing apathy and depression, determining an appropriate test treatment, selecting relevant secondary outcomes, recruiting participants, and deciding on a suitable method for treatment unmasking." | 5.17 | Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET). ( Bachman, D; Drye, LT; Herrmann, N; Lanctôt, KL; Mintzer, JE; Rosenberg, PB; Scherer, RW, 2013) |
| "To systematically review the literature on the therapeutic use of amphetamine, lisdexamfetamine and methylphenidate in elderly population with and without dementia." | 5.05 | Amphetamine Use in the Elderly: A Systematic Review of the Literature. ( Colpo, GD; John, V; Rocha, NP; Sassi, KLM; Teixeira, AL, 2020) |
| "The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) found that methylphenidate was effective in treating apathy with a small-to-medium effect size but showed heterogeneity in response." | 4.31 | Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial. ( Brawman-Mintzer, O; Craft, S; Herrmann, N; Lanctôt, KL; Lerner, AJ; Levey, AI; Mintzer, J; Padala, KP; Padala, PR; Perin, J; Porsteinsson, AP; Rivet, L; Rosenberg, PB; Sankhe, K; Shade, D; Tumati, S; van Dyck, CH; Vieira, D, 2023) |
| "Methylphenidate provides a safe and effective alternative to tricyclic antidepressants in medically ill populations but appears to be less effective in the presence of delirium." | 3.68 | Methylphenidate in depressed medically ill patients. ( Ahmed, I; Hurwitz, S; Rosenberg, PB, 1991) |
| "Hospital charts were reviewed for 66 medical and surgical patients who received dextroamphetamine or methylphenidate to treat a depressive disorder." | 3.67 | Psychostimulant treatment of depressive disorders secondary to medical illness. ( Cassem, NH; Murray, GB; Tesar, GE; Woods, SW, 1986) |
| "Methylphenidate was effective in 'normalizing' the decision-making behavior of patients, such that they became less risk taking on medication, although there were no significant effects on other aspects of cognitive function, including working memory, attentional set shifting, and reversal learning." | 2.72 | Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. ( Clark, L; Hodges, JR; Mehta, MA; Nestor, PJ; Rahman, S; Robbins, TW; Sahakian, BJ, 2006) |
| " By measuring the brain function using computer period analysis of cerebral biopotentials, dose-efficacy relations were found (in the range of 25-75 mcg) which suggest the bioavailability of LHM at the CNS level." | 2.64 | Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram. ( Akpinar, S; Herrmann, WM; Itil, TM, 1975) |
| "Frontotemporal dementia is an underdiagnosed illness with predominant behavioral and executive manifestations." | 1.32 | Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study. ( Goforth, HW; Konopka, L; O'Donnell, K; Patel, R; Poprawski, T; Primeau, M; Rao, M; Ruth, A; Shirazi, P, 2004) |
| "Bereavement after diagnosing AIDS or other HIV disease, psychological symptoms secondary to brain disease and the social consequences of having AIDS all interact to produce a devastating illness where the patient may be intensely grieving, demented and totally rejected by all of society." | 1.27 | Psychosocial aspects of AIDS. ( Goldmeier, D, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (50.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 2 (10.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kirkman, MA | 3 |
| Day, J | 3 |
| Gehring, K | 3 |
| Zienius, K | 3 |
| Grosshans, D | 3 |
| Taphoorn, M | 3 |
| Li, J | 3 |
| Brown, PD | 3 |
| Lanctôt, KL | 2 |
| Rivet, L | 1 |
| Tumati, S | 1 |
| Perin, J | 1 |
| Sankhe, K | 1 |
| Vieira, D | 1 |
| Mintzer, J | 1 |
| Rosenberg, PB | 3 |
| Shade, D | 1 |
| Lerner, AJ | 1 |
| Padala, PR | 1 |
| Brawman-Mintzer, O | 1 |
| van Dyck, CH | 1 |
| Porsteinsson, AP | 1 |
| Craft, S | 1 |
| Levey, AI | 1 |
| Padala, KP | 1 |
| Herrmann, N | 2 |
| Sassi, KLM | 1 |
| Rocha, NP | 1 |
| Colpo, GD | 1 |
| John, V | 1 |
| Teixeira, AL | 1 |
| Ter Keurst, A | 1 |
| Tuerlings, JHAM | 1 |
| Bertholet, EA | 1 |
| Wijnen, HW | 1 |
| Drye, LT | 1 |
| Scherer, RW | 1 |
| Bachman, D | 1 |
| Mintzer, JE | 1 |
| Ishida, T | 1 |
| Suga, A | 1 |
| Akagi, M | 1 |
| Kamei, C | 1 |
| BARUCCI, M | 1 |
| MORI, F | 1 |
| DARVILL, FT | 1 |
| WOOLLEY, S | 1 |
| Goforth, HW | 1 |
| Konopka, L | 1 |
| Primeau, M | 1 |
| Ruth, A | 1 |
| O'Donnell, K | 1 |
| Patel, R | 1 |
| Poprawski, T | 1 |
| Shirazi, P | 1 |
| Rao, M | 1 |
| Rahman, S | 1 |
| Robbins, TW | 1 |
| Hodges, JR | 1 |
| Mehta, MA | 1 |
| Nestor, PJ | 1 |
| Clark, L | 1 |
| Sahakian, BJ | 1 |
| Hales, RE | 1 |
| Hershey, SC | 1 |
| Reisberg, B | 1 |
| Ferris, SH | 1 |
| Gershon, S | 1 |
| Branconnier, RJ | 1 |
| Cole, JO | 1 |
| Klein, DF | 1 |
| Arcand, M | 1 |
| Hottin, P | 1 |
| Pritchard, JG | 1 |
| Mykyta, LJ | 1 |
| Itil, TM | 1 |
| Herrmann, WM | 1 |
| Akpinar, S | 1 |
| Ahmed, I | 1 |
| Hurwitz, S | 1 |
| Goldmeier, D | 1 |
| Woods, SW | 1 |
| Tesar, GE | 1 |
| Murray, GB | 1 |
| Cassem, NH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment Study for Frontotemporal Dementia[NCT00088751] | 20 participants | Observational | 2004-07-23 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for methylphenidate and Dementia
| Article | Year |
|---|---|
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Amphetamine Use in the Elderly: A Systematic Review of the Literature.
Topics: Aged; Amphetamine; Dementia; Depressive Disorder, Major; Humans; Lisdexamfetamine Dimesylate; Methyl | 2020 |
[Apathetic geriatric patient benefits from methylphenidate].
Topics: Aged; Aged, 80 and over; Aging; Apathy; Dementia; Depression; Female; Humans; Male; Methylphenidate; | 2017 |
Psychopharmacologic issues in the diagnosis and treatment of organic mental disorders.
Topics: Adrenal Cortex Hormones; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Delirium; Dementia; | 1984 |
Pharmacotherapy of senile dementia.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Amphetamine; Antidepressive Agents, Tricyclic; Dementia | 1980 |
[Treatment of depression in the elderly. The use of psychostimulants].
Topics: Age Factors; Aged; Amphetamines; Comorbidity; Contraindications; Dementia; Depressive Disorder; Huma | 1993 |
3 trials available for methylphenidate and Dementia
| Article | Year |
|---|---|
Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET).
Topics: Apathy; Dementia; Double-Blind Method; Humans; Methylphenidate; Randomized Controlled Trials as Topi | 2013 |
Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia.
Topics: Aged; Central Nervous System Stimulants; Cognition; Dementia; Double-Blind Method; Female; Gambling; | 2006 |
Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram.
Topics: Adolescent; Adult; Aged; Biological Availability; Child; Child, Preschool; Clinical Trials as Topic; | 1975 |
11 other studies available for methylphenidate and Dementia
| Article | Year |
|---|---|
Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Apathy; Cholinesterase Inhibitors; Dementia; Fe | 2023 |
Effects of anti-dementia drugs on morphine-induced somnolence.
Topics: Animals; Dementia; Donepezil; Electroencephalography; Electromyography; Indans; Male; Memantine; Met | 2009 |
[Effects of reserpine combined with a psycho-analeptic drug on mental efficiency of the aged].
Topics: Aged; Arteriosclerosis; Central Nervous System Stimulants; Dementia; Mental Disorders; Methylphenida | 1957 |
Double blind evaluation of methylphenidate (ritalin) hydrochloride; its use in the management of institutionalized geriatric patients.
Topics: Dementia; Disease Management; Double-Blind Method; Humans; Mental Disorders; Methylphenidate; Patien | 1959 |
Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study.
Topics: Aged; Brain Mapping; Central Nervous System Stimulants; Dementia; Electroencephalography; Humans; Ma | 2004 |
The therapeutic role of methylphenidate in senile organic brain syndrome.
Topics: Aged; Anxiety; Confusion; Dementia; Depression; Double-Blind Method; Electroencephalography; Factor | 1980 |
Clinical and biological aspects of depression in the elderly.
Topics: Aged; Dementia; Depression; Doxepin; Humans; Imipramine; Methylphenidate; Middle Aged; Trazodone | 1980 |
Use of a combination of methylphenidate and oxprenolol in the management of physically disabled, apathetic, elderly patients: a pilot study.
Topics: Aged; Dementia; Drug Therapy, Combination; England; Female; Hospitalization; Humans; Long-Term Care; | 1975 |
Methylphenidate in depressed medically ill patients.
Topics: Adjustment Disorders; Adult; Aged; Aged, 80 and over; Cerebrovascular Disorders; Clinical Trials as | 1991 |
Psychosocial aspects of AIDS.
Topics: Acquired Immunodeficiency Syndrome; Attitude to Health; Brain Diseases; Child; Dementia; Dextroamphe | 1987 |
Psychostimulant treatment of depressive disorders secondary to medical illness.
Topics: Adjustment Disorders; Adult; Aged; Dementia; Depression; Depressive Disorder; Dextroamphetamine; Fem | 1986 |